Product References — Single Donor Human Complement Serum

Single Donor Human Complement Serum from Innovative Research was used in the following study:   Cytoprotective IgG Antibodies in Sera from a Subset of Patients with AQP4‑IgG Seropositive Neuromyelitis Optica Spectrum Disorder LukmaneeTradtrantip, Michael R. Yeaman & A. S. Verkman Scientific Reports November 9, 2021 Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune disorder that attacks the central nervous system and can cause demyelination in the optic nerve, spinal cord, and brain, and potentially cause further neurological deficits. Over 70% of patients suffering from NMOSD are seropositive for IgG autoantibodies which target extracellular epitopes of astrocyte water channel aquaporin-4 (AQP4),...

Single Donor Human Whole Blood, Single Donor Human Plasma (Blood Derived), Single Donor Human Complement Serum, Innovative Grade US Origin Porcine Plasma, and Innovative Grade US Origin Porcine Whole Blood from Innovative Research were used in the following study:   Development of a Sensitive Assay to Screen Nanoparticles in vitro for Complement Activation Nuzhat Maisha, Tobias Coombs, and Erin B. Lavik American Chemical Society July 6, 2020 Nanomedicines are often recognized by the innate immune system as a threat, leading to unwanted clearance due to complement activation. This unwanted reaction not only alters the bioavailability of the therapeutic, but can...

Single Donor Human Complement Serum from Innovative Research was used in the following study:   Human CTLA4-Ig therapy can give false-positive anti-pig antibody results in primates after xenotransplantation Qi Li, Takayuki Yamamoto, Hayato Iwase, Huy Quoc Nguyen, Yi Wang, David Ayares, David K.C.Cooper, Hidetaka Hara Transplant Immunology December 2019 “…Background: Measurement of serum anti-pig antibodies is an important parameter in immune monitoring after pig-to-nonhuman primate xenotransplantation. Pig aortic endothelial cells (pAECs) are commonly used for this purpose. However, human (h) CTLA4-Ig (abatacept/belatacept) could bind to pCD80/86 on the cells, and a secondary antibody (i.e., anti-human IgG) may recognize hCTLA4-Ig (in...

Human Complement from Innovative Research was used in the following study:   CD55 upregulation in astrocytes by statins as potential therapy for AQP4-IgG seropositive neuromyelitis optica Lukmanee Tradtrantip, Tianjiao Duan, Michael R. Yeaman, Alan S. Verkman Journal of Neuroinflammation December 2019, 16:57 "... Neuromyelitis optica spectrum disorder (herein called NMO) is an inflammatory demyelinating disease that can be initiated by binding of immunoglobulin G autoantibodies (AQP4-IgG) to aquaporin-4 on astrocytes, causing complement-dependent cytotoxicity (CDC) and downstream inflammation. The increased NMO pathology in rodents deficient in complement regulator protein CD59 following passive transfer of AQP4-IgG has suggested the potential therapeutic utility...

Human Complement from Innovative Research was used in the following study:   Complement-dependent bystander injury to neurons in AQP4-IgG seropositive neuromyelitis optica Tianjiao Duan, Alex J. Smith and Alan S. Verkman Journal of Neuroinflammation, October 2018 "... Specified concentrations of AQP4-IgG (or control human IgG, Thermo Fisher Scientific, Rockford, IL) and human complement (Innovative Research, Novi, MI) were added in Hank’s buffer, and cells were incubated at 37 °C for specified times. In some experiments, cells were exposed to serum of an AQP4-IgG seropositive NMO patient who met the revised diagnostic criteria for clinical disease. A fixable dead-cell stain (amine-reactive dye,...